Q-linea AB (publ) engages in the manufacturing and sale of instruments and consumables diagnose and treat infectious diseases in the United Kingdom and European Union. The company offers ASTar, an antimicrobial susceptibility testing (AST) technology used in the treatment of bloodstream infections and sepsis; and ASTar BC G- Kit which contains two disposables, including a sample preparation cartridge and an AST disc, used with the Frozen insert. It also develops Podler, a portable blood culture unit for incubating and detecting growth in blood bottles. The company serves physicians, hospitals, laboratories, healthcare payers, and the medical profession. The company was incorporated in 2007 and is headquartered in Uppsala, Sweden.
Frequently asked questions
What sector does Q-linea AB (publ) (3F8) operate in?
Q-linea AB (publ) belongs to the Healthcare sector and operates in the Medical Devices industry.
What is Q-linea AB (publ) (3F8) current stock price?
As of the latest data, Q-linea AB (publ) stock price is €4.05, with a previous close of €4.05.
What is Q-linea AB (publ) (3F8) current market capitalization?
Q-linea AB (publ) market cap is approximately 26.04 billion.
What is Q-linea AB (publ) (3F8) Earnings Per Share (EPS)?
The trailing EPS is -€136.02.
Does Q-linea AB (publ) (3F8) pay dividends?
No. Q-linea AB (publ) does not pay a dividend.
What is Q-linea AB (publ) (3F8) beta (volatility) score?
Q-linea AB (publ) has a beta of 1.000, meaning its volatility is roughly in line with the market.
